Search
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen
go.drugbank.com/drugs/DB16902ApprovedThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16903ApprovedWithdrawnThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Singapore/WUH4618/2021 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16910ApprovedThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Darwin/11/2021 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16914ApprovedWithdrawnThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Delaware/55/2019 CVR-45 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16915ApprovedWithdrawnThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16919ApprovedWithdrawnThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Oxyfedrine
go.drugbank.com/drugs/DB13398ExperimentalCategories: Compounds used in a research, industrial, or household settingInfluenza A virus A/Croatia/10136RV/2023 X-425A (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB21765ApprovedThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/West Virginia/30/2022 (H1N1) Recombinant Hemagglutinin Antigen
go.drugbank.com/drugs/DB17995ApprovedWithdrawnThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Influenza A virus A/Georgia/12/2022 CVR-167 (H1N1) Antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB17996ApprovedThis defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen